Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Articles|October 31, 2022
Daily Dose: Low-carb Diet May Help Improve Untreated HbA1c
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 26, 2022, we reviewed a study published in JAMA Network Open that analyzed the effect of a behavioral intervention promoting a low-carbohydrate diet compared with usual diet on 6-month changes in HbA1c among persons with elevated untreated HbA1c.
The study
Adults aged 40-70 years with untreated HbA1c of 6.0% to 6.9% were randomized to a low-carbohydrate diet intervention (target <40 net grams of carbohydrates during the first 3 months; <60 net grams for months 3 to 6) or usual diet. The low-carbohydrate diet group received dietary counseling.
Researchers identified 2722 participants for potential study inclusion of which 962 were screened and a total of 150 were randomized equally to the low-carbohydrate dietary intervention or to the usual diet intervention.
The results
Adherence to the low-carbohydrate dietary intervention was associated with significantly greater reductions at 6 months in HbA1c (net difference, –0.23% [95% CI, –0.32% to –0.14%]; P<.001), fasting plasma glucose (–10.3 mg/dL [95% CI, –15.6 to –4.9 mg/dL]; P<.001), and body weight (–5.9 kg [95% CI, –7.4 to –4.4 kg]; P<.001) compared to adherence to usual diet.
Author's Conclusion
“In this 6-month randomized clinical trial, a low-carbohydrate diet intervention led to larger reductions in HbA1c than usual diet among adults with elevated untreated HbA1c (6.0–6.9%), though we were unable to assess its effects independently of weight loss. This dietary approach may be an option for people with or at high risk of T2D to improve glycemic and other markers and should be studied further and over longer time periods in other populations and settings."
Click here for the full study review.
Advertisement
Related to this article
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Advertisement
Advertisement